

Winter 2025 Funding Cancer Research: Innovative. Agile. Experienced.

Cancer Research & Treatment Fund held its annual fundraising dinner on Thursday November 21, 2024



Dr. Richard T. Silver (L) receiving the Humanitarian award from Dr. Anne Moore

L-R: Tom Silver, Richard T. Silver, Anne Moore, Ellen Ritchie and Ruth Fein Revell

Ruth Fein Revell (R) receiving the Cancer Survivor Award from Dr. Ellen Ritchie

On Thursday November 21, 2024, Cancer Research & Treatment Fund held its annual fundraiser, the Cancer Survivors Hall of Fame Dinner. Each year this dinner honors survivors, humanitarians, and medical professionals for their commitment to raising awareness and supporting life-saving research.

This year Anne Moore, MD presented the Humanitarian Award to CR&T Founder, Vice-President, and Medical Director Richard T. Silver, MD. Dr. Moore revealed that to further honor Dr. Silver's contributions to CR&T, the hematology/oncology community, and beyond, starting in 2024, the award will be named the Richard T. Silver, MD Humanitarian Award.

Ruth Fein Revell was honored by Ellen Ritchie, MD, who presented her with this year's Cancer Survivors award. Ruth has encouraged many others by sharing her story of "SurThriving" her chronic cancer, even authoring her latest book: *The Big C²*: stories from the chronic side of cancer.

Both honorees emphasized the importance of research in finding a cure for cancer, and the impact of supporting Cancer Research & Treatment Fund as CR&T continues its mission of funding cancer research.

For ways you can support CR&T's mission visit www.crt.org or contact the CR&T office (212.288.6604 or info@crt.org)



Magician Tom Pesce (R) works his magic with Diane Silver (L) and the crowd at the cocktail hour.

Board members Adam Silver (L) and Caleb Sexton

continued from page 1



To see all the photos from the 2024 Cancer Survivors Hall of Fame Dinner, visit www.crt.org/honorees

Save The Date! November 20, 2025: CR&T's Hall of Fame Survivors Dinner

The Lymphoma, Leukemia & Myeloma Congress

he Lymphoma, Leukemia & Myeloma Congress was held at the Sheraton Hotel in New York City October 16-19, 2024. This annual event is chaired by Dr. Morton Coleman, former Director of the Center for Lymphoma & Myeloma & Clinical Professor of Medicine, and CR&T's Associate Medical Director. The LLM Congress is co-chaired by Ruben Niesvizky, MD; Richard R. Furman, MD; Gail J. Roboz, MD; Jeremy Heinerich, PA-C; and John P. Leonard, MD - CR&T's 2024 Lifetime Achievement Recipient and Medical Advisory Board Member.

It is one of the largest conferences of its kind in the world drawing over 1,200 attendees from 40 countries and virtually

every state in the United States. The conference assembles some of the foremost experts in the world on hematologic cancer who bring the latest information regarding these diseases to the audience comprised of researchers, practitioners, and students in health care. Being asked to speak at the conference is considered a prestigious invitation.

The 2025 Lymphoma, Leukemia & Myeloma Congress will be held on Wednesday, October 15 - Saturday, October 18, 2025, and on the Congress' Leukemia Day, a special lecture will be permanently named to honor Dr. Richard T. Silver.

16th International Congress on Myeloproliferative Neoplasms (MPN Congress)



Abstract award winners with MPN Congress members.



Kichard T Silver, MD (CR&T Vice President and Medical Director) and Jerry L Spivak, MD (CR&T Medical Advisory Board Member) Co-Chaired the 16th International Congress on Myeloproliferative Neoplasms, on November 2-3, with a record number of participants.

The MPN Congress is an annual event hosted by Melton Medical Education, LLC, with two full days of sessions and presentations that provide a unique forum for the exchange of timely and relevant information about the pathogenesis, diagnosis and treatment of MPNs for attendees from around the world.

The Congress also recognizes submitted abstracts, and Katie Erdos, a (CR&T-funded) Research Program Assistant, was awarded the 2024 Most Outstanding Abstract.

General session



CR&T's 13th International Patient Symposium on MPNs

CR&T hosted its 13th International Patient Symposium on MPNs at Weill Cornell Medicine in New York City. The program featured presentations by distinguished scientists and clinical research physicians from the world's leading MPN Centers. The presentations were recorded and can be viewed on our website at: www.crt.org/mpn-patient-symposium-videos







Presenter Dr. Rampal


Q&A Session

Presenter Dr. Feldman

Thank you to our Individual and Foundation Sponsors

Mr. & Mrs. David & Laine Boule; Victor Frankiv – in honor of Ghaith Abu-Zeinah, MD; Inessa Gold; Debra and Donald Sciaretta – in honor of Ghaith Abu-Zeinah, MD; Ms. Diane Sherman – in honor of Terry Hermanson; M.A. and Chip Quinn – in honor of Ghaith Abu-Zeinah, MD; Herman Goldman Foundation

Thank you to our Corporate Sponsors



MARK YOUR CALENDARS

October 15-18, 2025: Lymphoma, Leukemia & Myeloma Congress

November 5, 2025: CR&T's 14th International Patient Symposium on MPNs

November 6-7, 2025: 17th International Congress on MPNs

November 20, 2025: CR&T's Hall of Fame Survivors Dinner

Research Publications

In 2024 CR&T-associated researchers published fourteen papers. In December, twenty abstracts were accepted at the American Society of Hematology Annual Meeting and in October, five abstracts were accepted at the 16th International MPN Congress.

The selection of these investigators' research by the various publications and conferences is a tribute to the quality of work accomplished with funding from CR&T.

To see the complete list of publications, visit the CR&T website - https://www.crt.org/research-updates

MPN CONGRESS 2024 ABSTRACTS

- Outcomes are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-matched Study
- Ropeginterferon Alfa-2b (ROPEG) and PeginterferonAlfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)
- Correlating Image-level Nucleomorphologic Features with Molecular Subtypes of Myeloproliferative Neoplasms
- Deep Learning Predicts JAK2, CALR, TET2, and ASXL1 Directly from Whole Slide Marrow Images
- Updated Long-term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera (PV) Patients: Hematocrit (Hct) Control and Therapeutic Phlebotomy (TP) frequency

ASH 2024 ABSTRACTS

- Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study
- · Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera
- Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)
- DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha
- · Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera
- Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms
- Deep Learning Predicts JAK2, Calr TET2, and ASXL1 directly from Whole Slide Marrow Images
- · Correlating Image-Level Nucleomorphologic Features with Molecular Subtypes of Myeloproliferative Neoplasms
- MPN Fitness: A Single-Cell, Single-Tube Measurement of the Pathobiology of MPNs
- HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis
- Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
- Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
- Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
- A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
 – Topline Results
- Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
- · Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia
- Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
- AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
- · Opening Pandora's Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia
- Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

To support the continuing research of CR&T-associated researchers, visit www.crt.org/donate or scan the QR code.



Katie Erdos awarded Outstanding Abstract at the 2024 MPN Congress







CR&T welcomes new Board Member Caleb Sexton. Caleb is Founder and CEO of Workforcely, a consulting firm focusing on workforce planning and the software tools that support it.

Caleb began his career as a software engineer, where he developed his technical skills and a passion for problem-solving. He transitioned into workforce management software, collaborating with clients across various sectors, including retail, healthcare, manufacturing, and logistics. Those experiences enriched his understanding of the challenges faced in workforce management and made for a logical move to create his own consulting firm.

Like many of us, Caleb and his family and friends have been affected by a diagnosis of cancer. Through his journey he has gained an understanding of cancer's impact. This journey has reinforced his belief in the value of research, support, and advocacy to help improve outcomes. These experiences have highlighted the critical importance of awareness and early detection.

Caleb was introduced to the work of the organization through his friend and CR&T Board Member, A.J. Shiekman. Caleb's connection with CR&T has grown over the years through his attendance of CR&T's Cancer Survivors Hall of Fame fundraising dinners. He felt inspired by the organization's commitment to funding cancer research and how vital it is for advancing treatments and improving patient outcomes. Witnessing the positive effects of this work on countless lives has motivated him to contribute to the CR&T's mission and support innovation in cancer research for future generations.

Caleb and his fiancé divide their time between Bozeman, Montana, and New York City, allowing them to enjoy both the beauty of nature and life in the city. Welcome Caleb.

he Harrington Discovery Institute, based at the University Hospitals of Cleveland and the Case Western Reserve School of Medicine, was founded in 2012. It began with a transformational gift of \$50 million from the Harrington family in Ohio. It has blossomed over the years into a globally recognized incubator for the most promising young physician-scientists, providing them with substantive research and laboratory support and linking them from the outset with organized commercialization opportunities. In 2012, **Dr. Andrew Schafer** was invited to give a gala keynote lecture at Cleveland's historic Severance Hall, on stage with the Ohio Governor at that time, John Kasich. Since then, Dr. Schafer has been invited 12 more times to give the opening lecture of the Institute's annual scientific symposium on the topic of "physician-scientists," the focus of Dr. Schafer's book, "The Vanishing Physician-Scientist?", and as a member of the NIH Director's Advisory Board for the cultivation and sustainability of physician-scientists.



Dr. Andrew Schafer



Dr. Anne Moore

CR&T is pleased to congratulate Medical Advisory Board Members Anne Moore, MD and Andrew Schafer, MD, for being honored with the prestigious title of Emerita and Emeritus, respectfully, by Weill Cornell Medicine. This well-deserved recognition celebrates their outstanding contributions to the field of hematology/oncology and their dedication to advancing medical research and patient care.

Both Dr. Moore and Dr. Schafer have been pillars in the medical community, and their exceptional work has left an indelible mark on the department of hematology/oncology at Weill Cornell. Their leadership, vision, and commitment to excellence have positively impacted countless lives. We at CR&T look forward to their continued input and insight on the Medical Advisory Board.

Congratulations Dr. Moore, Professor Emerita of Clinical Medicine and Dr. Schafer, Professor Emeritus of Medicine.

Expanding CR&T's Impact

Our work would not be possible without the generous support of our donors and grantors. We are deeply grateful for your commitment to CR&T's mission. We gratefully acknowledge our supporters who provided gifts in 2024.

Partners in Excellence

The Fried Foundation Julia Johns Marilyn Schuster Bharat Shah and Family Incyte Corporation Sobi Inc. Pharmaessentia

Founders

David Boule John Duffy Michael Clark Friel Eli Hoffman Kasia McCormick S Jay Mermelstein Anne Moore And Arnold Lisio John Quinn Richard And Edith Rose Debra Sciaretta Diane Sherman Richard T. Silver The Audrey Love Charitable Foundation Karyopharma Therapeutics Inc. GlaxoSmithKline LLC (GSK) Morphosys Us Inc. Estate Of Janice M. Zlendic New York Presbyterian Hospital Herman Goldman Foundation Protagonist Therapeutics

Patrons

Nelson Boxer Louis J. Briskman Keith and Patricia Civil Michael And Jennifer Johns Friel Terry Hermanson Judy o. Higgins Charles Kushner Nick And Pat Ohnell - The Ohnell Family Foundation Jane Phillips-Conroy Jeffrey Puglisi Thomas M. Silver Adam Silver Anne Templeton Amanda L. Johns Family Trust

Dr. Naveen Pemmaraju Named the Richard T. Silver, MD Visiting Professor

Established in 1998 with a major gift from Cancer Research & Treatment Fund (CR&T), the Richard T. Silver, MD Visiting Professorship is named in honor of CR&T's founder. The lecture is given by a distinguished speaker from another institution, with the aim of broadening the horizons and perspective of practitioners in the field of hematology oncology. Attendance is open to the entire faculty, fellows, and house staff of the WCM Department of Medicine, including the Division of Medical Oncology. Physicians from Lower Manhattan, New York-Presbyterian Queens, Rockefeller University, Memorial Sloan Kettering Cancer Center, The Hospital for Special Surgery, and private practitioners are also invited to attend.

The 2025 Richard T. Silver MD Visiting Professorship was held at Weill Cornell Medicine (WCM) on January 15, 2025. Introduced by Gail J Roboz, MD, Director of the Leukemia Program, this year's speaker was Naveen Pemmaraju, MD, Professor, Department of Leukemia, Division of Cancer, Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program, Executive Director for Cancer Medicine (MDACC Cancer Network) - MD Anderson Cancer Center (MDACC) in Houston, Texas. Dr. Pemmaraju presented on "MPNs in 2025 & Beyond: Clinical Pearls for the Internist."

Dr. Pemmaraju completed his internal medicine training at Johns Hopkins in the Osler Medical Program, completed hematology/ oncology training at MD Anderson Cancer Center Fellowship Program, obtained ABIM board certification in internal medicine, hematology and oncology. He is a world-leading clinical researcher in the area of rare myeloid malignancies including BPDCN, MPN, and AML. His clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young and older adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML). He has authored/co-authored over 370+ papers. In addition, Dr Pemmaraju is a well-regarded clinician and medical educator, having been awarded the Gerald P. Bodey Excellence in Teaching Award at MDACC in 2020, the MPN Hero Award in 2022, the Faculty Educator of the Year in 2023 for MDACC and the MDACC Community Outreach Faculty Excellence Award in 2023. CR&T and WCM were proud to have welcomed Dr. Pemmaraju as this year's Richard T. Silver, MD Visiting Professor.



L-R: Drs. Ritchie, Silver, Scandura, Pemmaraju, Roboz, and Wolf (Chair, Weill Department of Medicine)

Herman Goldman Foundation Sumitomo Pharma America, Inc. Takeda Pharmaceuticals USA, Inc.

Leaders

Joseph Aimi Jr John Altmeyer Edward P And Abby Ambinder Sally Bloostein Joseph Bradley John Burger Allison F Cheston Marilyn Clark Rabbi Joshua M. Davidson Naomi Glaser Eckstein Alfred Feliu

John Frederick Mark Goldman Nathan Gordon Eve Hall Adam Heyman Jackie And Sol M. Israel Charitable Fund Warren Lammert Douglas McCormick Jr Gloria Miller Thomas Nussbaum John O'Hare Peter And Suzanne Emil Pleskunas Kenneth Rosenbaum Jean Rosensaft Joseph Ruocco Caleb Sexton

Todd J. Shaw And Kristen B. Kane Patrick Shaw Margo And David Shaw AJ Shiekman Tim Silver Jacob Silver Harold Sparrow Alexander Swistel Mark Teich W Preston Tollinger Gordana Vlahovic Harry Wagner Stephen Wilson NYS Laborers' Health And Safety Trust Fund Stuart S Applebaum Giving Foundation

Visit www.crt.org/thanks-to-our-donors for the complete list of our donors who are all helping to make a difference!



Cancer Research & Treatment Fund, Inc. (CR&T) 500 E. 77th Street, Suite 1001 New York, NY 10162 Phone: 212-288-6604 Email: info@crt.org www.crt.org

ABOUT CR&T

Since 1968, CR&T has funded the world's most promising physician-scientists, equipping them with the resources to advance the treatment of various types of blood cancers, including myeloproliferative neoplasms (MPNs), leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma, as well as other common cancers, such as breast and lung cancer.

STAFF

Chad Feay, MA, CHES Director of Administration and Development Mara Sanderson Administrative Specialist

CR&T NEWS

Writer: Chad Feay, MA CHES Designer: Zenaida Mendoza Printer: WW Printing Corp

Board of Directors

Thomas M. Silver, President Principal, Silver Dollar Ventures, LLC

Richard T. Silver, MD, Vice President, Medical Director Weill Cornell Medicine

David T. Boule, Treasurer Retired Partner, Ernst & Young

Nelson A. Boxer, Counsel Partner, Petrillo Klein & Boxer LLP

Maria Brisbane, CFA Managing Director, Morgan Stanley

Terry Hermanson President, Mr. Christmas, Inc.

Michael C. Kempner Managing General Partner, KS Capital Partners, L.P.

Kasia McCormick Amanda Johns Perez

Jeffrey Puglisi, MD Glenville Medical Concierge Care

Richard J. Rose Senior Managing Director (retired), Shufro, Rose & Co., LLC

Caleb Sexton Founder and CEO, Workforcely

Rajesh Shah, PhD Chief Investment Officer - The Hardy Group

Todd J. Shaw First Vice President, Morgan Stanley

AJ Shiekman Strategy/Business Development Manager, Pure Storage

Adam Silver Tim Silver Portfolio Manager, Empery Asset Management, LP Medical Advisory Board Richard T. Silver, MD Vice President & Medical Director Weill Cornell Medicine, New York, NY

Morton Coleman, MD Associate Scientific Director New-York Presbyterian Hospital/Weill Cornell Medicine, New York, NY

Mark W. Pasmantier, MD Associate Medical Director New-York Presbyterian Hospital/Weill Cornell Medicine, New York, NY

Ghaith Abu Zeinah, MD New-York Presbyterian Hospital/Weill Cornell Medicine, New York, NY

Edward P. Ambinder, MD Icahn School of Medicine at Mount Sinai, New York, NY

John P. Leonard, MD New-York Presbyterian Hospital/Weill Cornell Center for Lymphoma and Multiple Myeloma, New York, NY

Anne Moore, MD Weill Cornell Breast Center, New York, NY

Malcolm Moore, DPhil Memorial Sloan Kettering Cancer Center, New York, NY

Shahin Rafii, MD Weill Cornell Medicine, New York, NY

Joseph M. Scandura, MD, PhD Weill Cornell Medicine, New York, NY

Andrew I. Schafer, MD Weill Cornell Medicine, New York, NY

David A. Scheinberg, MD, PhD Memorial Sloan Kettering Cancer Center, New York, NY

Jerry L. Spivak, MD Johns Hopkins Medicine, Baltimore, MD

Alexander J. Swistel, MD New-York Presbyterian Hospital/Weill Cornell Breast Center, New York, NY

Anne Templeton

CR&T News at your fingertips!

See the latest news, download an issue to your tablet or digital device, and browse archived issues!



CR&T Newsletters are published 3 times a year. Stay up to date on the latest CR&T developments in cancer research and treatments! Sign up for emails at www.crt.org/sign-up and follow us on social media!

(Facebo

(Facebook) @cancerresearchandtreatment

(X-formerly Twitter) @CRTFund

(LinkedIn) cancer-research-&-treatment-fund-inc

(YouTube) @cancerresearchtreatmentfund

www.instagram.com/cancerresearchtreatmentfund





Cancer Research & Treatment Fund 500 East 77th Street, Suite 1001 New York, NY 10162-0015



Funding Cancer Research: Innovative. Agile. Experienced.

